{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:11:24Z","timestamp":1792098684500,"version":"4.4.0"},"reference-count":39,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To evaluate the efficacy and safety of monthly and <jats:italic>pro re nata<\/jats:italic> (PRN, guided by visual acuity stabilization and disease activity criteria) ranibizumab regimens in Chinese patients with neovascular age\u2010related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This double\u2010masked study randomized nAMD patients (1:1) to ranibizumab monthly from baseline to Month (M) 11 to a PRN regimen from M12 to M23 (monthly group, <jats:italic>n<\/jats:italic>\u00a0=\u00a0167) versus ranibizumab three monthly doses followed by a PRN regimen up to M23 (PRN group, <jats:italic>n<\/jats:italic>\u00a0=\u00a0166). Subgroups were assessed based on the presence\/absence of PCV (indicated by indocyanine green angiography).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 334 randomized patients, 41.7% had PCV at baseline. Mean average best\u2010corrected visual acuity (BCVA) change from M3 to M4 through M12 was 3.3 letters with monthly and 1.7 letters with PRN (mean difference: 1.6; 95% CI: \u22122.95, \u22120.20, primary end\u2010point). Mean change in BCVA from baseline (monthly\/PRN, 53.8\/53.7) to M12 and M24 was 12.3 and 11.3 letters in monthly and 9.6 and 9.3 letters in PRN group. Corresponding values for patients with PCV\/without PCV were 12.7\/12.1 letters (M12) and 12.3\/10.6 letters (M24) in monthly and 9.4\/9.4 letters (M12) and 9.7\/8.7 letters (M24) in PRN groups. The mean number of injections was 11.4 (monthly) and 8.2 (PRN) from Day 1 to M11 and 4.8 (monthly) and 5.0 (PRN) from M12 to M23. No new safety findings were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The study results support the use of either ranibizumab monthly or PRN regimens in Chinese patients with nAMD, regardless of presence of PCV.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aos.14588","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T20:54:49Z","timestamp":1609361689000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Two different treatment regimens of ranibizumab 0.5\u00a0mg for neovascular age\u2010related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study"],"prefix":"10.1111","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0536-2951","authenticated-orcid":false,"given":"Xiaoxin","family":"Li","sequence":"first","affiliation":[{"name":"Peking University People's Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhu","sequence":"additional","affiliation":[{"name":"China Novartis Institutes for Biomedical Research Co., Ltd. Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Egger","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Chang","sequence":"additional","affiliation":[{"name":"China Novartis Institutes for Biomedical Research Co., Ltd. Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department Ophthalmology, Inselspital Bern University Hospital University of Bern Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9666-5482","authenticated-orcid":false,"given":"Yanping","family":"Song","sequence":"additional","affiliation":[{"name":"Wuhan General Hospital of Guangzhou Military Command Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"West China Hospital Sichuan University Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangtian","family":"Dong","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Xu","sequence":"additional","affiliation":[{"name":"Shanghai First People's Hospital Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Weisberger","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,30]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.10.018"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.014"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"e_1_2_5_6_1","first-page":"343","article-title":"Profile of ranibizumab: efficacy and safety for the treatment of wet age\u2010related macular degeneration","volume":"8","author":"Chen Y","year":"2012","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_5_7_1","first-page":"1802","article-title":"One\u2010year real\u2010world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study","volume":"11","author":"Chen SN","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.04.001"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.05.033"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.08.002"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000526"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-303444"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.009"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.12.019"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.05.011"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2010.03.004"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.08.012"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31824f91e8"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.4030"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.04.018"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-012-1970-3"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.01.024"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.1804"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.03.047"},{"key":"e_1_2_5_25_1","first-page":"237","article-title":"Early treatment of exudative age\u2010related macular degeneration with ranibizumab (Lucentis(R)): the key to success","volume":"108","author":"Matthe E","year":"2011","journal-title":"Ophthalmologe"},{"key":"e_1_2_5_26_1","unstructured":"Ogura Y Lee W Cheung G Jaffee G D\u2019Souza D Alam J&Koh Aet al. (2019):The efficacy and safety of brolucizumab compared with aflibercept in polypoidal choroidal vasculopathy: 24 month results from the HAWK study. Presented at the 19th EURETINA congress September 5\u20138 Paris France."},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01236-x"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.05.024"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2006.00736.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.09.004"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-015-0022-7"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.05.035"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.022"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2010.02065.x"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-013-2562-6"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.04.002"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.02.027"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.01.010"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-014-0106-1"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14588","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aos.14588","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T16:39:12Z","timestamp":1693327152000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.14588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1111\/aos.14588"],"URL":"https:\/\/doi.org\/10.1111\/aos.14588","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,30]]},"assertion":[{"value":"2019-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}